2023 saw key developments in the biotech industry, with notable breakthroughs in Alzheimer’s disease treatments, obesity management, and cancer therapy. There were also significant strides in artificial intelligence (AI) and mRNA technology. Key highlights include FDA’s approval of the Alzheimer’s treatment, LEQEMBI, developed by Eisai Co. and Biogen Inc., advancements in obesity treatments such as GLP-1 analogues, and gene therapies, the approval of world’s first CRISPR-based therapy, Casgevy, by the UK, and AI-powered drug repurposing.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
